1. Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis?
- Author
-
D'haeseleer M, Hostenbach S, Peeters I, Sankari SE, Nagels G, De Keyser J, and D'hooghe MB
- Subjects
- Blood Flow Velocity, Humans, Inflammation metabolism, Inflammation pathology, Inflammation physiopathology, Brain Ischemia metabolism, Brain Ischemia pathology, Brain Ischemia physiopathology, Cerebrovascular Circulation, Cognition Disorders metabolism, Cognition Disorders pathology, Cognition Disorders physiopathology, Diffuse Axonal Injury metabolism, Diffuse Axonal Injury pathology, Diffuse Axonal Injury physiopathology, Endothelin-1 metabolism, Multiple Sclerosis metabolism, Multiple Sclerosis pathology, Multiple Sclerosis physiopathology
- Abstract
The exact pathogenesis of multiple sclerosis (MS) is incompletely understood. Although auto-immune responses have an important role in the development of hallmark focal demyelinating lesions, the underlying mechanism of axonal degeneration, the other key player in MS pathology and main determinant of long-term disability, remains unclear and corresponds poorly with inflammatory disease activity. Perfusion-weighted imaging studies have demonstrated that there is a widespread cerebral hypoperfusion in patients with MS, which is present from the early beginning to more advanced disease stages. This reduced cerebral blood flow (CBF) does not seems to be secondary to loss of axonal integrity with decreased metabolic demands but appears to be mediated by elevated levels of the potent vasospastic peptide endothelin-1 in the cerebral circulation. Evidence is evolving that cerebral hypoperfusion in MS is associated with chronic hypoxia, focal lesion formation, diffuse axonal degeneration, cognitive dysfunction, and fatigue. Restoring CBF may therefore emerge as a new therapeutic target in MS.
- Published
- 2015
- Full Text
- View/download PDF